Related Experiment Video
Updated: Aug 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Mechanisms underlying reduction of clinical events in lipid lowering trials
1University of British Columbia, Vancouver Hospital and Health Sciences Centre.
Insights
Lipid lowering therapies significantly reduce clinical events, likely through plaque stabilization. This concept explains improvements beyond modest angiographic changes in coronary artery disease trials.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Lipid lowering trials show significant reductions in clinical events.
- Angiographic improvements in these trials are often modest and do not fully explain clinical benefits.
Purpose of the Study:
- To explore emerging hypotheses for the discrepancy between clinical event reduction and angiographic changes in lipid lowering trials.
- To introduce the concept of plaque stabilization as a unifying explanation.
Main Methods:
- Selective literature review of recent lipid lowering trials and related research.
Main Results:
- Lipid lowering improves atherothrombotic and vasomotor processes, including endothelial function.
- Plaque composition influences lesion susceptibility to acute disruption.
- These factors contribute to the concept of plaque stabilization.
Conclusions:
- Plaque stabilization integrates functional and morphological factors affected by lipid lowering.
- This concept offers a potential explanation for the observed reductions in clinical events in lipid lowering trials.
Objective:
To outline the emerging hypotheses explaining the reductions in clinical events in trials of lipid lowering.
Design:
Selective literature review.
Main Results:
The primary angiographic end-points of recent lipid lowering trials, justified largely from a hemodynamic paradigm of coronary disease, have been shown to improve significantly but modestly. The improvements appear out of keeping with the more impressive trends in reducing clinical events. There are many possible explanations for these results. Prominent among these is the influence of lipid lowering on the atherothrombotic and vasomotor processes, including endothelially mediated ones, which underlie both plaque rupture and plaque progression. Additionally, there is now a greater appreciation of the role of constituents of plaques, especially moderate ones, in rendering lesions either susceptible or resistant to acute disruption. In aggregate, these newer areas of emphasis have led to the concept of plaque stabilization.
Conclusions:
Plaque stabilization is a new concept encompassing many functional and morphological factors that are influenced in the short and long term by aggressive lipid lowering. This concept may help explain reductions in clinical events noted in lipid lowering trials.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management